CL2022001988A1 - Sistema terapéutico transdérmico que comprende ingrediente rotigotina y adhesivo de silicona no resistente a mina - Google Patents

Sistema terapéutico transdérmico que comprende ingrediente rotigotina y adhesivo de silicona no resistente a mina

Info

Publication number
CL2022001988A1
CL2022001988A1 CL2022001988A CL2022001988A CL2022001988A1 CL 2022001988 A1 CL2022001988 A1 CL 2022001988A1 CL 2022001988 A CL2022001988 A CL 2022001988A CL 2022001988 A CL2022001988 A CL 2022001988A CL 2022001988 A1 CL2022001988 A1 CL 2022001988A1
Authority
CL
Chile
Prior art keywords
therapeutic system
transdermal therapeutic
resistant silicone
rotigotine
silicone adhesive
Prior art date
Application number
CL2022001988A
Other languages
English (en)
Inventor
Benda Christian
Kolling Ulrike
Schurad Björn
Wauer Gabriel
Original Assignee
Luye Pharma Switzerland Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Luye Pharma Switzerland Ag filed Critical Luye Pharma Switzerland Ag
Publication of CL2022001988A1 publication Critical patent/CL2022001988A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Inorganic Chemistry (AREA)
  • Psychology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La invención se refiere a un sistema terapéutico transdérmico (TTS) para la administración del principio activo rotigotina que comprende una capa de matriz que contiene rotigotina, uno o más adhesivos de silicona no resistentes a amina en una cantidad de más de 50 % en peso, con base en el peso total del adhesivo sensible a la presión de la capa de matriz, y parafina, así como métodos para la preparación de estos. El sistema terapéutico transdérmico de acuerdo con la invención es particularmente adecuado para el tratamiento de la enfermedad de Parkinson.
CL2022001988A 2020-01-24 2022-07-22 Sistema terapéutico transdérmico que comprende ingrediente rotigotina y adhesivo de silicona no resistente a mina CL2022001988A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP20153621.6A EP3854388B1 (de) 2020-01-24 2020-01-24 Transdermales therapeutisches system mit dem wirkstoff rotigotin und mindestens einem nicht aminresistenten silikonkleber

Publications (1)

Publication Number Publication Date
CL2022001988A1 true CL2022001988A1 (es) 2023-05-19

Family

ID=69191982

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2022001988A CL2022001988A1 (es) 2020-01-24 2022-07-22 Sistema terapéutico transdérmico que comprende ingrediente rotigotina y adhesivo de silicona no resistente a mina

Country Status (17)

Country Link
US (1) US20230218539A1 (es)
EP (2) EP3854388B1 (es)
JP (1) JP2023511964A (es)
KR (1) KR20220131941A (es)
CN (1) CN115279351A (es)
AU (1) AU2021210611A1 (es)
BR (1) BR112022014665A2 (es)
CA (1) CA3165453A1 (es)
CL (1) CL2022001988A1 (es)
CO (1) CO2022011900A2 (es)
DK (1) DK3854388T3 (es)
ES (1) ES2966170T3 (es)
FI (1) FI3854388T3 (es)
MX (1) MX2022009114A (es)
PL (1) PL3854388T3 (es)
PT (1) PT3854388T (es)
WO (1) WO2021148634A1 (es)

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4591622A (en) 1984-10-29 1986-05-27 Dow Corning Corporation Silicone pressure-sensitive adhesive process and product thereof
US4655767A (en) 1984-10-29 1987-04-07 Dow Corning Corporation Transdermal drug delivery devices with amine-resistant silicone adhesives
US5989586A (en) 1992-10-05 1999-11-23 Cygnus, Inc. Two-phase matrix for sustained release drug delivery device
DE19814084B4 (de) 1998-03-30 2005-12-22 Lts Lohmann Therapie-Systeme Ag D2-Agonist enthaltendes transdermales therapeutisches System zur Behandlung des Parkinson-Syndroms und Verfahren zu seiner Herstellung
DE19830898A1 (de) 1998-07-10 2000-01-13 Hexal Ag Vorrichtung zur Verbesserung der Entnahmefähigkeit von in Beuteln verpackten, haftklebend ausgerüsteten, flächigen Substratabschnitten
US6337086B1 (en) 1999-02-06 2002-01-08 Dow Corning Corporation Pressure sensitive adhesive compositions for transdermal drug delivery devices
EP1318843B1 (en) 2000-09-19 2013-04-17 Henkel AG & Co. KGaA Acryl adhesive useful in transdermal drug delivery systems
ES2203563T3 (es) 2001-05-08 2004-04-16 Schwarz Pharma Ag Sistema terapeutico transdermico mejorado para el tratamiento de la enfermedad de parkinson.
PT1256339E (pt) 2001-05-08 2004-02-27 Lohmann Therapie Syst Lts Sistema terapeutico transdermico para doenca de parkinson que induz niveis plasmaticos altos de rotigotina
DE10220230A1 (de) 2002-05-06 2003-11-27 Sanol Arznei Schwarz Gmbh Verwendung von Rotigotine zur Behandlung des Restless Leg Syndroms
EP1386605A1 (en) 2002-07-30 2004-02-04 Schwarz Pharma Ag Improved transdermal delivery system for the administration of rotigotine
EP1386604A1 (en) 2002-07-30 2004-02-04 Schwarz Pharma Ag Improved transdermal delivery system
DE10234673B4 (de) 2002-07-30 2007-08-16 Schwarz Pharma Ag Heißschmelz-TTS zur Verabreichung von Rotigotin und Verfahren zu seiner Herstellung sowie Verwendung von Rotigotin bei der Herstellung eines TTS im Heißschmelzverfahren
DE10261696A1 (de) 2002-12-30 2004-07-15 Schwarz Pharma Ag Vorrichtung zur transdermalen Verabreichung von Rotigotin-Base
DE10334188B4 (de) 2003-07-26 2007-07-05 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung von Depressionen
DE10361259A1 (de) 2003-12-24 2005-07-28 Schwarz Pharma Ag Verwendung von Rotigotine in einem Frühstadium von Morbus Parkinson zur Prävention des weiteren Neuronenverlustes
DE102004014841B4 (de) 2004-03-24 2006-07-06 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung und Prävention des Parkinson-Plus-Syndroms
MX2010005925A (es) 2007-11-28 2010-08-02 Ucb Pharma Gmbh Nueva forma polimorfico de rotigotina y proceso para la produccion.
NZ589542A (en) 2008-05-30 2012-10-26 Mylan Inc Transdermal drug delivery system comprising an active agent in amorphous form and polyvinylpyrrolidone
DE102009052972A1 (de) 2009-11-12 2011-09-15 Lts Lohmann Therapie-Systeme Ag Verfahren zur Verhinderung der Kristallisation von Arzneistoffen in einem Polymerfilm
EA025584B1 (ru) 2009-12-22 2017-01-30 ЮСиБи ФАРМА ГМБХ Поливинилпирролидон для стабилизации твердой дисперсии некристаллической формы ротиготина
EP2457565A1 (de) 2010-11-29 2012-05-30 Ratiopharm GmbH Transdermales therapeutisches System enthaltend Rotigotin
WO2012084969A1 (en) 2010-12-22 2012-06-28 Hexal Ag Adhesive composition containing rotigotine and transdermal therapeutic system comprising the adhesive composition
TW201431570A (zh) * 2012-11-22 2014-08-16 Ucb Pharma Gmbh 用於經皮投服羅替戈汀（Ｒｏｔｉｇｏｔｉｎｅ）之多天式貼片
EP3007685A1 (de) * 2013-06-14 2016-04-20 tesa Labtec GmbH Dreischichtiges transdermales therapiesystem (tts)
EP3145503A1 (en) * 2014-05-20 2017-03-29 LTS Lohmann Therapie-Systeme AG Method for adjusting the release of active agent in a transdermal delivery system

Also Published As

Publication number Publication date
KR20220131941A (ko) 2022-09-29
EP3854388A1 (de) 2021-07-28
FI3854388T3 (fi) 2023-11-27
PL3854388T3 (pl) 2024-02-26
CA3165453A1 (en) 2021-07-29
EP3854388B1 (de) 2023-10-04
DK3854388T3 (da) 2023-11-27
PT3854388T (pt) 2023-12-11
BR112022014665A2 (pt) 2022-10-11
CN115279351A (zh) 2022-11-01
CO2022011900A2 (es) 2022-10-31
ES2966170T3 (es) 2024-04-18
AU2021210611A1 (en) 2022-08-18
MX2022009114A (es) 2022-10-27
WO2021148634A1 (de) 2021-07-29
EP4093383A1 (de) 2022-11-30
US20230218539A1 (en) 2023-07-13
JP2023511964A (ja) 2023-03-23

Similar Documents

Publication Publication Date Title
AR093481A1 (es) Parche de varios dias para la administracion transdermica de rotigotina
AR073704A1 (es) Sistema de administracion transdermal de droga para principios activos liquidos que tiene una capa de matriz adhesiva que incluye un ingrediente farmaceutico activo que es seleccionado entre selegilina y rivastigmina
CY1116638T1 (el) Διαδερμικο θεραπευτικο συστημα για την χορηγηση μιας δραστικης ουσιας
CY1120283T1 (el) Διαδερμικο θεραπευτικο συστημα για την χορηγηση ριβαστιγμινης ή παραγωγων αυτης
BR112012004696B8 (pt) composto modulador da atividade de tlr, seu uso, composição farmacêutica, medicamento, kit e combinação
CY1117964T1 (el) Αντιψυχωτικη ενεσιμη συνθεση μακρας διαρκειας δρασης τεχνικος τομεας
HRP20050828B1 (hr) Uv-stabilni transdermalni flaster
BRPI0719006B8 (pt) sistemas terapêuticos transdérmicos com alto índice de utilização de substância ativa e exatidão de dosagem
MX2019007389A (es) Sistema terapeutico transdermico que contiene asenapina y polisiloxano o poliisobutileno.
BR112012032282A2 (pt) administração transdérmica de memantina
CR20150360A (es) Sistema de liberación transdérmica
BR112019006955A2 (pt) métodos de controle da dor usando dispositivos de distribuição transdérmica de dexmedetomidina
CO6640335A2 (es) Tratamiento terapéutico para síndrome metabólico, diabetes de tipo 2, obesidad o prediabetes
AR063782A1 (es) Parche y metodo transdermico para emesis
BR112012030641A2 (pt) métodos e composições para terapia farmacêutica oral
BR112017008993A2 (pt) métodos e composições especificamente para o tratamento de transtorno de déficit de atenção
CR20220550A (es) Inhibidores macrocíclicos de las peptidilarginina deiminasas
MX2020003667A (es) Sistema terapeutico transdermico para la administracion transdermica de guanfacina que comprende un polimero de silicona.
EA201300648A1 (ru) Трансдермальная терапевтическая система (tts), содержащая ротиготин
CL2022001988A1 (es) Sistema terapéutico transdérmico que comprende ingrediente rotigotina y adhesivo de silicona no resistente a mina
CL2021001463A1 (es) Preparación de absorción percutánea que comprende donepezilo estabilizado
AR028525A1 (es) Sistema terapeutico transdermal para la administracion de lerisetron
MX2021012709A (es) Sistema terapeutico transdermico.
AR108939A1 (es) Sistema de administración transdérmica que contiene metilfenidato o sus sales, y métodos de este
PE20220943A1 (es) Composiciones farmaceuticas resistentes a la descarga de dosis que comprenden venirunad